Key result
High oxaliplatin concentration was an independent risk factor for the development of vascular pain.
Why the study?
Oxaliplatin frequently causes vascular pain, but the risk factors remain unclear and prevention methods have not been established.
Does high oxaliplatin concentration increase the risk of vascular pain in patients receiving chemotherapy?
Observational (n=32)
No
Does high oxaliplatin concentration increase the risk of vascular pain in patients receiving chemotherapy?
High oxaliplatin concentration (>358.5 mg/L) is a significant risk factor for chemotherapy-induced vascular pain, suggesting that further dilution may reduce its incidence.
This is the authors' abstract. We don't add key points for this paper.
WHAT IS KNOWN AND OBJECTIVE: Oxaliplatin (L-OHP) is an antineoplastic agent that frequently causes vascular pain. However, the risk factors for vascular pain are unclear, and prevention methods have not been established. We retrospectively investigated patients who were treated with L-OHP to examine the influence of patient characteristics and concomitant analgesic use on the incidence of vascular pain. METHODS: We collected information about the presence or absence of vascular pain, age, sex, treatment dose and analgesic use of patients who received L-OHP at Tokyo Medical University Hachioji Medical Center. We analysed the relevance of each factor between the vascular pain onset and non-onset groups. RESULTS AND DISCUSSION: Thirty-two patients (average age: 68.6 years; 69.8% and 30.2% men and women, respectively) were classified into the vascular pain onset (n = 64) and non-onset groups (n = 68). The multivariate logistic regression analysis revealed that L-OHP concentration (>358.5 mg/L) was an independent determinant of vascular pain development (odds ratio: 2.422, 95% CI: 1.117-5.252). Intergroup differences in age, sex, body mass index, non-steroidal anti-inflammatory drug use, and underlying pain from cancer and other comorbidities were not significant. WHAT IS NEW AND CONCLUSION: High L-OHP concentration was identified as a significant risk factor for L-OHP-induced vascular pain. Our results indicate that the dilution of L-OHP may reduce the incidence of vascular pain.
Answers are grounded in this paper and cite their sources.
High oxaliplatin concentration may raise vascular pain risk; hypothesis-generating for dilution, needs prospective confirmation.
No takes yet. Share an insight, caveat, or question.
Matsunuma et al. (2021) conducted an observational in Patients treated with oxaliplatin (n=32). High oxaliplatin concentration (>358.5 mg/L) vs. Lower oxaliplatin concentration was evaluated on Vascular pain development (OR 2.422, 95% CI 1.117-5.252). High oxaliplatin concentration was an independent risk factor for the development of vascular pain.
Synapse has enriched 10 related papers. Consider them for comparative context: